PeterEllisMD

PubMed

• 18 citations
  Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting
  Casey Mason, Peter G. Ellis, Kathy Lokay, Amanda Barry, Natalie R. Dickson, Ray D. Page, Blase N. Polite, Ravi Salgia, Michael A. Savin, Corey Shamah, Mark A. Socinski> ;Journal of Clinical Pathways. 2018 Jan 1
• 8 citations
  Perspectives on the Use of Clinical Pathways in Oncology Care.
  Anne C. Chiang, Peter Ellis, Robin Zon> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2017 Jan 1
• 8 citations
  Pathways Clinical Decision Support for Appropriate Use of Key Biomarkers.
  Peter G. Ellis, Adam Brufsky, Sushil Beriwal, Kathleen Lokay, Hans Benson, Stephanie McCutcheon, Melinda Krebs> ;Journal of Oncology Practice. 2016 May 24
• 24 citations
  The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis.
  R Chowdhury, Balaji Ganeshan, S Irshad, Katherine Lawler, M Eisenblätter, Hanna Milewicz, Manuel Rodriguez-Justo, Kenneth Miles, Peter R. Ellis, Ashley M. Groves, Shon...> ;The British Journal of Radiology. 2014 Apr 17
• 4 citations
  Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel...
  Sheeba Irshad, Cheryl Gillett, Sarah E Pinder, Roger A'Hern, Mitch Dowsett, Ian O. Ellis, Jms Bartlett, Judith M Bliss, Andrew M Hanby, S.R.D. Johnston, Peter Barrett-...> ;Breast Cancer Research and Treatment. 2014 Feb 12
• 11 citations
  Development and Implementation of Oncology Care Pathways in an Integrated Care Network: The Via Oncology Pathways Experience
  Peter G. Ellis> ;Journal of Oncology Practice. 2013 May 1
• 1 citations
  Payer and provider collaborations that improve quality outcomes in oncology.
  Jeffrey D Dunn, Peter G Ellis, John L Fox, Ira Klein, Maria Lopes, David B. Nash, Lynn Nishida, Lee S. Schwartzberg, Winston Wong> ;Managed Care. 2010 Nov 1
• 1 citations
  A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer.
  David M. Loesch, Lina Asmar, Vikki A. Canfield, Gregory A. Parker, Harry E. Hynes, Peter G. Ellis, William A. Ferri, Nicholas J. Robert> ;Breast Cancer Research and Treatment. 2003 Jan 1
• Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy.
  Ellis PA, Smith IE, Detre S, Burton SA, Salter J, A'Hern R, Walsh G, Johnston SR, Dowsett M> ;Breast Cancer Res. Treat.. 1998-03-01
• A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration.
  McKeage MJ, Mistry P, Ward J, Boxall FE, Loh S, O'Neill C, Ellis P, Kelland LR, Morgan SE, Murrer B> ;Cancer Chemother. Pharmacol.. 1995-01-01
• 4 citations
  Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer.
  David C. Smith, Duncan I. Jodrell, Merrill J. Egorin, Roy M. Ambinder, Eleanor G. Zuhowski, Willi Kreis, Peter G. Ellis, Donald L. Trump> ;Cancer Chemotherapy and Pharmacology. 1993 Jan 1
• 175 citations
  High-Dose Oral Tamoxifen, a Potential Multidrug-Resistance-Reversal Agent: Phase I Trial in Combination With Vinblastine
  Donald L. Trump, David C. Smith, Peter G. Ellis, Miriam P. Rogers, S. Clifford Schold, Eric P. Winer, Timothy J. Panella, V. Craig Jordan, Robert L. Fine> ;Journal of the National Cancer Institute. 1992 Dec 2
• Join now to see all